Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Belite Bio, Inc - American Depositary Shares (NQ: BLTE ) 50.33 +1.68 (+3.45%) Streaming Delayed Price Updated: 4:00 PM EDT, Jul 19, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 68,079 Open 48.72 Bid (Size) 48.51 (1) Ask (Size) 50.78 (3) Prev. Close 48.65 Today's Range 48.72 - 50.66 52wk Range 14.44 - 50.15 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Belite Bio to Present at the JonesHealthcare Seaside Summit July 08, 2024 From Belite Bio, Inc Via GlobeNewswire Belite Bio Receives Sakigake (Pioneer Drug) Designation of Tinlarebant for Stargardt Disease in Japan June 12, 2024 From Belite Bio, Inc Via GlobeNewswire Performance YTD +17.70% +17.70% 1 Month +1.37% +1.37% 3 Month +45.46% +45.46% 6 Month +9.77% +9.77% 1 Year +214.56% +214.56% More News Read More Belite Bio to Participate in the Benchmark’s 4th Annual Healthcare House Call Investor Conference May 14, 2024 From Belite Bio, Inc Via GlobeNewswire Expert Ratings for Belite Bio December 14, 2023 Via Benzinga BLTE Stock Earnings: Belite Bio Misses EPS for Q1 2024 May 14, 2024 Via InvestorPlace Belite Bio Reports First-Quarter 2024 Financial Results and Provides Corporate Update May 13, 2024 From Belite Bio, Inc Via GlobeNewswire Belite Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference May 13, 2024 From Belite Bio, Inc Via GlobeNewswire Belite Bio to Host Webcast on May 14, 2024, to Discuss First Quarter 2024 Financial Results May 08, 2024 From Belite Bio, Inc Via GlobeNewswire Belite Bio to Participate in Key Opinion Leader Webinar to Discuss Unmet Needs In Stargardt Disease (STGD1) and Geographic Atrophy (GA) and Perspectives On Tinlarebant May 06, 2024 From Belite Bio, Inc Via GlobeNewswire Belite Bio Presents Additional Analysis from Phase 2 Study of Tinlarebant in Stargardt Disease at the ARVO Annual Meeting May 06, 2024 From Belite Bio, Inc Via GlobeNewswire Belite Bio Announces Presentation at the Association for Research in Vision and Ophthalmology 2024 Annual Meeting May 01, 2024 From Belite Bio, Inc Via GlobeNewswire Belite Bio Announces $25 Million Registered Direct Offering April 25, 2024 From Belite Bio, Inc Via GlobeNewswire Belite Bio Announces PMDA Submission of Tinlarebant for Stargardt Disease Clinical Trial in Japan March 22, 2024 From Belite Bio, Inc Via GlobeNewswire Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website March 11, 2024 From Belite Bio, Inc Via GlobeNewswire Belite Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update March 11, 2024 From Belite Bio, Inc Via GlobeNewswire Belite Bio to Host Webcast on March 12, 2024, to Discuss Fourth Quarter and Full Year 2024 Financial Results March 06, 2024 From Belite Bio, Inc Via GlobeNewswire Belite Bio to Participate in the Leerink Partners Global Biopharma Conference March 04, 2024 From Belite Bio, Inc Via GlobeNewswire Belite Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference February 07, 2024 From Belite Bio, Inc Via GlobeNewswire Belite Bio to Participate in the Benchmark Company’s Upcoming Discovery One-on-One Investor Conference November 30, 2023 From Belite Bio, Inc Via GlobeNewswire Belite Bio to Participate in the BTIG Ophthalmology Day November 20, 2023 From Belite Bio, Inc Via GlobeNewswire Belite Bio Reports Third Quarter 2023 Operational Highlights and Financial Results November 13, 2023 From Belite Bio, Inc Via GlobeNewswire Deutsche Bank ADR Investor Conference: Presentations Now Available for Online Viewing November 10, 2023 From Virtual Investor Conferences Via GlobeNewswire Belite Bio to Host Webcast on November 14, 2023, to Discuss Third Quarter 2023 Financial Results November 07, 2023 From Belite Bio, Inc Via GlobeNewswire Belite Bio, Inc. to present at the Deutsche Bank ADR Virtual Investor Conference on 8 November 2023 November 06, 2023 From Virtual Investor Conferences Via GlobeNewswire Belite Bio Presents Results from a 24-month, Phase 2 Study of Tinlarebant in Childhood-onset Stargardt Disease at the AAO Annual Meeting November 06, 2023 From Belite Bio, Inc Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
